Delving into the Latest Updates on Aspirin Zinc with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

COXs

Action

inhibitors

Mechanism

COX inhibitors(Cyclooxygenases inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

FeverPain

Inactive Indication-

Originator Organization

Espero Pharmaceuticals, Inc.

Active Organization

Chifeng Wanze Intelligent Medicine Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC9H8O4Zn

InChIKeyOEGRZPQWZAPGKS-UHFFFAOYSA-N

CAS Registry70875-96-6

View All Structures (2)

Does Aspirin reduce inflammation in the walls of unruptured brain aneurysms?
Brain aneurysms are balloon-like outpouchings of a blood vessel resulting from a weakness in the vessel wall. They generally cause no symptoms, but can burst and cause a bleed in the brain, resulting in death or disability. Aneurysms occur in 1 in 30 people, but rarely burst, with 1 in 10,000 people having a brain bleed.
Ideally, aneurysms would be treated before they burst to prevent bleeding in the brain. The two ways of treating aneurysms currently are both risky and invasive, and no medications have been shown to reduce the risk of aneurysms bursting.
Aspirin is one of the most common medications, used worldwide to treat pain, fever and inflammation, and for the prevention of strokes and heart attacks. Its anti-inflammatory properties may be beneficial for patients with aneurysms. We know that the walls of burst aneurysms and aneurysms that are about to burst, are more inflamed than those that do not burst. Therefore, a drug that reduces inflammation may reduce the risk of an aneurysm bursting.
We have designed this study to test whether there is a measurable reduction in inflammation in walls of brain aneurysms.
In this study, participants known to have an aneurysm that is not planned for treatment and has not yet burst, take aspirin daily for three months, and have an MRI scan before and after to look for a reduction in inflammation.
If this study is successful it would be the first step towards developing the first medication to help treat patients with aneurysms, representing a huge advance for the 2.1 million people in the UK with this condition.

Start Date24 Oct 2019

Sponsor / Collaborator

University Hospital Southampton NHS Foundation Trust

100 Clinical Results associated with Aspirin Zinc

Login to view more data

100 Translational Medicine associated with Aspirin Zinc

Login to view more data

100 Patents (Medical) associated with Aspirin Zinc

Login to view more data

45,143

Literatures (Medical) associated with Aspirin Zinc

01 Jun 2025·Separation and Purification Technology

Unraveling the competitive cocrystallization behavior of natural products and impact of intermolecular interactions on their stability

Author: Xu, Li ; Gong, Zhuoshan ; Li, Detao ; Ouyang, Jinbo ; Zhou, Limin ; Heng, Jerry ; Zhao, Yan ; Shehzad, Hamza ; Ning, Zichen

Design of natural product cocrystals and its formation mechanism are of great significance importance to the development of fields such as medicine, food, cosmetics, and agriculture.In this research, alkaloids (theophylline, theobromine) and polyhydroxy natural products (quercetin, resveratrol, naringin) were selected as the research subjects.Through competitive cocrystal experiments, the study explored the stability differences among different cocrystals.Based on theor. calculations, the study determined the hydrogen bonds and π-π bonds within the crystals were identified.Combined with cocrystal structure anal., we discussed the influence of hydrogen bonding networks and π-π stacking modes on cocrystal stability.According to these results, the study correlated the cocrystal stability with void level, establishing the void formula to predict the stability between different cocrystals.Addnl., it summarized the structural unit cell model of natural product cocrystals, revealing formation mechanism of cocrystals, and intuitively demonstrating effect of intermol. interactions on stability of crystal.Finally, we proposed the stability law, establishing a close connection between intermol. interactions, void level, and cocrystal stability, providing a theor. basis for exploring relationship between cocrystal microstructure and stability.

01 May 2025·Desalination

Enhanced performance of thin film nanocomposite (TFN) membranes by incorporating hydrophilic MOF-808 into the organic phase: Towards eliminating non-steroidal anti-inflammatory drugs (NSAIDs) from aqueous solutions

Author: Nasiri, Masoud ; Abdi, Sara

The aim of this study is to remove non-steroidal anti-inflammatory drugs (NSAIDs) using polyethersulfone (PES)/MOF-808@polyamide (PA) thin film nanocomposite (TFN) membranes.The structure of the synthesized MOF-808 particles was confirmed using the Fourier transform IR (FTIR) spectroscopy, X-ray diffraction (XRD) and field emission SEM (FESEM) analyses.The pure water permeability and the rejection rate of salts containing monovalent and divalent anions such as NaCl, Na₂SO₄, MgCl₂ and MgSO₄ were investigated following the structure identification of these TFN membranes.The obtained nanofiltration membranes were employed to eliminate aspirin, naproxen and mefenamic acid from aqueous solutionsThe mol. dynamics (MD) simulation was utilized to investigate how adding triethylamine (TEA) to the aqueous phase affects the diffusion rate of piperazine (PIP) monomer in the formation process of the PA layer via the interfacial polymerization (IP).Introducing the MOF-808 particles into the organic phase of the IP reaction significantly improves the hydrophilicity of the thin film nanocomposite membranes due to the addition of hydrophilic hydroxyl groups to the membrane surface.The performance of the TFN membranes illustrated that by increasing the loading of MOF-808 particles from 0.03 wt% to 0.1 wt%, the rejection percentage of NaCl, Na₂SO₄, MgCl₂ and MgSO₄ salts enhanced from 27.95 % to 45.5 %, from 97.16 % to 97.55 %, from 16.1 % to 23.15 % and from 63.22 % to 79.85 %, resp.The conducted experiments indicated that the MOF-808@PA TFN membranes, with a higher reversible to total resistance ratio compared to the TFC membrane, could be a suitable candidate for separating each of the three studied NSAIDs from aqueous solutions

01 Apr 2025·Seminars in Thrombosis and Hemostasis

Pharmacotherapy for Venous Thromboprophylaxis following Total Hip or Knee Arthroplasty: A Systematic Review and Network Meta-analysis

Article

Author: Arya, Roopen ; Tan, Chuen Seng ; Li, Ruiqi ; Ho, Sean Wei Loong ; Ramanathan, Kollengode ; Yong, Bryan Song Jun ; Ling, Ryan Ruiyang ; Rochwerg, Bram ; Poh, Jane Wenjin ; Fan, Bingwen Eugene

AbstractThe optimal pharmacological prophylaxis for venous thromboembolism (VTE) after hip or knee arthroplasty is uncertain. We conducted a systematic review and network meta-analysis to compare the efficacy and safety of various medications. We searched multiple databases for randomized clinical trials (RCTs) comparing medications (including factor Xa inhibitors, factor IIa inhibitor, warfarin, unfractionated heparin [UFH], low-molecular-weight heparin [LMWH], aspirin, pentasaccharide) for VTE prophylaxis post-arthroplasty. Outcomes included any postoperative VTE identified with screening, major bleeding, and death. We used LMWH as the main comparator for analysis and performed trial sequential analysis (TSA) for each pairwise comparison. Certainty of evidence was assessed using GRADE (Grading of Recommendations, Assessments, Developments and Evaluations). We analyzed 70 RCTs (55,841 participants). Factor Xa inhibitors decreased postoperative VTE significantly compared with LMWH (odds ratio [OR]: 0.55, 95% confidence interval [CI]: 0.44–0.68, high certainty). Pentasaccharides probably reduce VTE (OR: 0.61, 95% CI: 0.36–1.02, moderate certainty), while the factor IIa inhibitor dabigatran may reduce VTE (OR: 0.75, 95% CI: 0.40–1.42, low certainty). UFH probably increases VTE compared with LMWH (OR: 1.31, 95% CI: 0.91–1.89, moderate certainty), and other agents like warfarin, aspirin, placebo, and usual care without thromboprophylaxis increase VTE (high certainty). Factor Xa inhibitors may not significantly affect major bleeding compared with LMWH (OR: 1.06, 95% CI: 0.81–1.39, low certainty). No medications had a notable effect on mortality compared with LMWH (very low certainty). TSA suggests sufficient evidence for the benefit of factor Xa inhibitors over LMWH for VTE prevention. Compared with LMWH and aspirin, factor Xa inhibitors are associated with reduced VTE after hip or knee arthroplasty, without an increase in bleeding and likely no impact on mortality.

100 Deals associated with Aspirin Zinc

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB00945

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Fever	China	Chifeng Wanze Intelligent Medicine Co., Ltd.	-
Pain	China	Chifeng Wanze Intelligent Medicine Co., Ltd.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02901067 (STAT, CTgov)	Phase 2	Acute Lung Injury \| Fibrinolysis Shutdown \| Venous Thromboembolism	43	Rosuvastatin+Aspirin (Experimental)	ecwdsbwizx(exovuqkqac) = wcaygqmsnd ilbidlrxqy (spbfbrhmjv, ygkenvalwx - vgdilsdvoo) View more	-	27 Apr 2023
				Rosuvastatin) (Control)	ecwdsbwizx(exovuqkqac) = bmhqnzacbi ilbidlrxqy (spbfbrhmjv, obwliwufyh - bnwycmxpab) View more
NCT03093246 (CTgov)	Phase 2/3	Aggressive Periodontitis	38	Full-mouth ultrasonic debridement (Control Group)	gcoyrlgvbb(gbcrsgcrmh) = dhrqzzjawt jqjatnmybu (flmgcrjvhy, ahfdcdjkqi - qyjgixetay) View more	-	29 Jul 2021
				Full-mouth ultrasonic debridement+Aspirin (Test Group)	gcoyrlgvbb(gbcrsgcrmh) = ysltjtfsvu jqjatnmybu (flmgcrjvhy, ajtwtlxgcn - hzrhyrtahc) View more
NCT03093207 (CTgov)	Phase 2/3	Residual Neoplasm \| Aggressive Periodontitis	34	Omega-3 polyunsaturated fatty acids+Aspirin (Test Group)	xferufjbyq(xzcrsindiw) = yjycanqycu incwbkyekr (sqdafgizdm, uewrpgkbwb - xsrwropjlg) View more	-	17 Nov 2020
				Placebo (Control Group)	xferufjbyq(xzcrsindiw) = xlhbcptctd incwbkyekr (sqdafgizdm, vkybwfvsee - xawmxihenf) View more
NCT00501059 (ARRIVE, CTgov)	Phase 3	Cardiovascular Diseases	12,546	Aspirin (Acetylsalicylic acid, BAYE4465) (Acetylsalicylic Acid (Aspirin, BAYE4465))	yiysyrhetg(hfrpvlqbwg) = uleymaauny dxlhwulell (kanxcsqmou, azfwukeumq - cwwtumxftz) View more	-	08 Jan 2018
				Placebo (Placebo)	yiysyrhetg(hfrpvlqbwg) = tjlkzgnecl dxlhwulell (kanxcsqmou, gsdxzihsbb - oaieytqjak) View more
NCT01429272 (Minocycline, CTgov)	Phase 3	Bipolar Disorder	99	placebo (Placebo & Placebo)	lsansxozfy(omqsmpcxuj) = gcydvdnzak kwvzfuqoaa (osujeqcvda, lqohmbuqct - gqunzwymre) View more	-	08 Nov 2017
				Aspirin+Minocycline (Minocycline & Aspirin)	lsansxozfy(omqsmpcxuj) = qawxdohdir kwvzfuqoaa (osujeqcvda, ywuincvgxg - joicjqvvul) View more
NCT02155985 (CTgov)	Phase 2	HIV Infections	121	Placebo+Aspirin (Aspirin 300 mg + Aspirin 100 mg Placebo)	zdspmygsdi(plhnkiasrl) = zclnmrkpwq nvdzhvahow (oygdhdlfpm, rbxaajupkh - ladpxkjasi) View more	-	07 Jul 2016
				Placebo+Aspirin (Aspirin 100 mg + Aspirin 300 mg Placebo)	zdspmygsdi(plhnkiasrl) = ehsxflbvdg nvdzhvahow (oygdhdlfpm, qtnguhtjud - umuxobklgr) View more
AUA2015	Not Applicable	Nephrosis	754	Aspirin during surgery	omxacphgut(thwgnwjnca) = gympizrnst ofabfybfbc (rsvlvxpoha ) View more	-	01 Apr 2015
				Chronic AP therapy preoperatively	omxacphgut(thwgnwjnca) = fbsgjvqlcn ofabfybfbc (rsvlvxpoha ) View more
NCT01426438 (CTgov)	Phase 2	Inflammation \| HIV Infections	99	Aspirin+Niacin (Arm A: Extended-release Niacin With Aspirin)	uwevaccrnm(bcatatdnir) = amstzzlogb hkfhkjvwvh (ufjlgvrcvb, jiqbuleyro - zwlpdarfjn) View more	-	21 Oct 2014
				Fenofibrate (Arm B: Fenofibrate)	uwevaccrnm(bcatatdnir) = nhrrvrhagn hkfhkjvwvh (ufjlgvrcvb, bnbzpnjhog - bahsywoufj) View more